Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum from the T-Dis Trial

Nicolas Penel; Emilie Decoupigny; Emmanuelle Tresch-Bruneel; Axel Le Cesne; Sophie Taieb; Nicolas Isambert

doi:10.1097/COC.0000000000000576

Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum from the T-Dis Trial

Nicolas Penel, Emilie Decoupigny, Emmanuelle Tresch-Bruneel, Axel Le Cesne, Sophie Taieb, Nicolas Isambert

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	737
Nombre de pages	1
journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	42
Numéro de publication	9
Les DOIs	https://doi.org/10.1097/COC.0000000000000576
état	Publié - 1 sept. 2019

Accès au document

10.1097/COC.0000000000000576

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Penel, N., Decoupigny, E., Tresch-Bruneel, E., Le Cesne, A., Taieb, S., & Isambert, N. (2019). Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum from the T-Dis Trial. American Journal of Clinical Oncology: Cancer Clinical Trials, 42(9), 737. https://doi.org/10.1097/COC.0000000000000576

@article{3d1099bfa4d449ba913531bf4cc68bad,

title = "Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum from the T-Dis Trial",

author = "Nicolas Penel and Emilie Decoupigny and Emmanuelle Tresch-Bruneel and {Le Cesne}, Axel and Sophie Taieb and Nicolas Isambert",

note = "Funding Information: T-Dis trial was supported through competitive national research (PHRC) grant from the National Cancer Institute of France (INCa) (netsarc.org). PharmaMar, S.A. had supplied the drug for the randomized part of the trial. PharmaMar, S.A. had no role in study design, collection, analysis, or interpretation of data. The corresponding author had full access to all of the data and the final responsibility to sub-mit for publication.",

year = "2019",

month = sep,

day = "1",

doi = "10.1097/COC.0000000000000576",

language = "English",

volume = "42",

pages = "737",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

number = "9",

}

Penel, N, Decoupigny, E, Tresch-Bruneel, E, Le Cesne, A, Taieb, S & Isambert, N 2019, 'Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum from the T-Dis Trial', American Journal of Clinical Oncology: Cancer Clinical Trials, VOL. 42, Numéro 9, p. 737. https://doi.org/10.1097/COC.0000000000000576

Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum from the T-Dis Trial. / Penel, Nicolas; Decoupigny, Emilie; Tresch-Bruneel, Emmanuelle et al.
Dans: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol 42, Numéro 9, 01.09.2019, p. 737.

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

TY - JOUR

T1 - Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient with Metastatic Undifferentiated Pleomorphic Sarcoma

T2 - Postscriptum from the T-Dis Trial

AU - Penel, Nicolas

AU - Decoupigny, Emilie

AU - Tresch-Bruneel, Emmanuelle

AU - Le Cesne, Axel

AU - Taieb, Sophie

AU - Isambert, Nicolas

N1 - Funding Information: T-Dis trial was supported through competitive national research (PHRC) grant from the National Cancer Institute of France (INCa) (netsarc.org). PharmaMar, S.A. had supplied the drug for the randomized part of the trial. PharmaMar, S.A. had no role in study design, collection, analysis, or interpretation of data. The corresponding author had full access to all of the data and the final responsibility to sub-mit for publication.

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85071499033&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000576

DO - 10.1097/COC.0000000000000576

M3 - Letter

C2 - 31449140

AN - SCOPUS:85071499033

SN - 0277-3732

VL - 42

SP - 737

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 9

ER -